[The characteristics of regulation of pharmaceutical market of the Eurasian Economical Union].

T G Marseva,I N Voblaia,E N Seifieva
DOI: https://doi.org/10.32687/0869-866X-2019-27-5-841-846
IF: 37.8
2019-11-27
Circulation
Abstract:The article considers one of the most pressing problems - the turnover of medicines within the common pharmaceutical market of the Eurasian Economic Union. The drug market is an essential aspect of social policy, reflecting general welfare of citizens and the level of the country's national security. The object of the study is the importation of medicines into the customs territory of the Eurasian Economic Union (EAEU), and the subject is the social and legal relationship when importing medicines, problems and ways to improve the procedure of importing medicines into the territory of the EAEU. At the present stage of development of civil society, a number of countries of the Commonwealth of Independent States are closely cooperating in improving the quality and level of living of population, complying with basic social guarantees, including providing affordable and high-quality medical and drug assistance. The indicator of country's development in the field of medicine is the ability to develop and to test drugs, because these processes are considered as the most complex, expensive and risky, as well as to control the circulation of drugs created by "pseudo-companies" producing counterfeits for well-known pharmaceutical companies. The problem of falsification leads to an outflow of capital outside the EEU, threat to health and lives of consumers, violation of the right holders' rights, discredit foundations of the state structure of the EEU member countries that are not able to provide guarantees for the safety of drug consumption. The creation of common pharmaceutical market within the Eurasian Economic Union will in the future not only provide control of circulation of medicines on the territory of the EAEU, but also contribute to the development of national pharmaceutical industry by expanding distribution channels and expanding range of drugs produced by foreign manufacturers established on the territory of the EAEU.
cardiac & cardiovascular systems,peripheral vascular disease
What problem does this paper attempt to address?